Изменятся ли наши предпочтения в выборе отдельных компонентов комбинированной антигипертензивной терапии в 2010 году?

1. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. JAMA 2003; 289: 2560–72.
2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
3. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск. тер. и проф. 2004; Прил.
4. Mancia G, Laurent St, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
5. Jamerson K, Weber MA, Bakris GL et al. for ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–26.
6. PROGRESS Collaborative Study Group. Randomized trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
7. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
8. Beckett NS, Peters R, Fletcher AE et al. for HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
9. Trenkwalder P, Schaetzl R, Borbas E et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 – the EXPRESS-C trial. J Hypertens 2007; 25 (Suppl. 2): S228 (abstr. P24.261).
10. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80.
11. Poldermans D, Glazer R, Karagianniss S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279–89.
12. Allemann Y, Fraile B, Lambert M et al. Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens 2008; 10: 1–10.
13. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22: 837–46.
14. Fogari R, Zoppi A, Mugellini A et al. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Cur Ther Res 1999; 60: 195–206.
15. Fogari R, Mugellini A, Zoppi A et al. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. Cur Ther Res 2000; 61: 669–79.
16. Fogari R, Mugellini A, Zoppi A et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Cur Ther Res 2002; 63: 1–14.
17. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE Randomised trial. Lancet 2004; 363: 2022–31.
18. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
19. Cohn JN, Tognoni G. A Randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.
20. Mochizuki S, Dahlof B, Shimizu M et al. for the Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
21. Sawada T, Yamada H, Dahlof B et al. for the KYOTO HEART Study Group. Effacts of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; doi 10.1093/eurheartj/ehp363.
22. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393–8.
23. Kasanuki H, Hagiwara N, Hosoda S et al. For the HIJ-CREATE investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
24. Dahlof B, Devereux RB, Kjeldsen SE et al. for LIFE Study Group. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
25. Schrader J, Luders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
26. Schrader J, Luders S, Kulschewski A et al. for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES). Stroke 2005; 36: 1218–24.
27. Yusuf S, Diener H-Ch, Sacco RL et al. for the PRoFESS study Group. Telmisartan to prevent Recurrent Stroke and Cardiovascular events. N Engl J Med 2008; 359: 1225–37.
28. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular events. N Engl J Med 2008; 358: 1547–1559.
29. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008doi: 10.1016/S0140–6736 (08)61242–8.

Ю.М.Лопатин

Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центр